AstraZeneca Full-Year and Q4 2018 Results
AstraZeneca PLC 14 February 2019 07:00 GMT Full-year and Q4 2018 results New launches and commercial execution deliver full-year sales growth and a very strong final quarter. 2019 anticipated to be a year of higher year-on-year sales growth combined with operating leverage. The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8% at CER1) to $5,768m. In the year, Product Sales increased by 4% to $21,049m, reflecting the performance of new medicines2 (+81%) and the sustained strength of Emerging Markets (+12%, +13%